Suchergebnisse

PubPharm (1.930)

1

Achievement of Very Low Low-Density Lipoprotein Cholesterol Levels : Is It Time to Unlearn Concern for Hemorrhagic Stroke?

enthalten in: Circulation | 2019

von Michos, E. | Martin, S.

CommentOn: Circulation. 2019 Dec 17;140(25):2054-2062. - PMID 31707788

2

Tocilizumab in patients with adult-onset Still's disease refractory to glucocorticoid treatment

enthalten in: Annals of the rheumatic diseases | 2019

von Lee, Y.

CommentOn: Ann Rheum Dis. 2018 Dec;77(12):1720-1729. - PMID 30279267

3

Are neutralising anti-VEGF or VEGFR2 antibodies necessary in the treatment of EGFR-mutated non-small-cell lung cancer?

enthalten in: The Lancet. Oncology | 2019

von Rosell, R. | Pedraz-Valdunciel, C.

CommentOn: Lancet Oncol. 2019 Dec;20(12):1655-1669. - PMID 31591063

4

Mogamulizumab Forecast : Clearer Patients, with a Slight Chance of Immune Mayhem

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2019

von Larocca, C. | Kupper, T. | LeBoeuf, N.

CommentOn: Clin Cancer Res. 2019 Dec 15;25(24):7275-7280. - PMID 31366601

5

Musculotendinous Inflammation : The Defining Pathology of Polymyalgia Rheumatica?

enthalten in: The Journal of rheumatology | 2019

von Owen, C. | Liew, D. | Buchanan, R.

CommentOn: J Rheumatol. 2019 Dec;46(12):1619-1626. - PMID 30877202

6

The 20% Rule of NASH Progression : The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH

enthalten in: Hepatology (Baltimore, Md.) | 2019

von Loomba, R. | Adams, L.

CommentOn: Hepatology. 2019 Dec;70(6):1913-1927. - PMID 30993748

7

Alternative dosing regimens for atezolizumab : right dose, wrong frequency

enthalten in: Cancer chemotherapy and pharmacology | 2019

von Goldstein, D. | Ratain, M.

CommentOn: Cancer Chemother Pharmacol. 2019 Dec;84(6):1257-1267. - PMID 31542806

8

Incorporating isatuximab in the treatment of multiple myeloma

enthalten in: Lancet (London, England) | 2019

von Trudel, S.

CommentOn: Lancet. 2019 Dec 7;394(10214):2096-2107. - PMID 31735560

9

Re : Dugel et al: HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration (Ophthalmology. 2019 Apr 12 [Epub ahead of print])

enthalten in: Ophthalmology | 2019

von Sharma, A. | Kumar, N. | Bandello, F.

CommentOn: Ophthalmology. 2020 Jan;127(1):72-84. - PMID 30986442

10

enthalten in: Ophthalmology | 2019

von Dugel, P. | Koh, A. | Ogura, Y. | +8

CommentOn: Ophthalmology. 2020 Jan;127(1):72-84. - PMID 30986442

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[193]